

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Pembrolizumab with enfortumab vedotin for untreated locally advanced or metastatic urothelial cancer ID6332

Provisional Stakeholder List

Consultees		Commentators (no right to submit or
		appeal)
Company		General
•	Merck Sharp and Dohme	All Wales Therapeutics and Toxicology
	(pembrolizumab)	Centre
•	Astellas (enfortumab vedotin)	Allied Health Professionals Federation
		Board of Community Health Councils in
Patient/carer groups		Wales
•	Action Bladder Cancer UK	 British National Formulary
•	Black Health Agency for Equality	Care Quality Commission
•	Bladder and Bowel Community	Department of Health, Social Services
•	Bladder and Bowel UK	and Public Safety for Northern Ireland
•	Cancer 52	Healthcare Improvement Scotland Medicines and Healthcare products
•	Cancer Black Care	Medicines and Healthcare products Pagulatory Agency
•	Cancer Equality	Regulatory AgencyNational Association of Primary Care
•	Fight Bladder Cancer Helen Rollason Cancer Charity	 National Association of Finnary Care National Pharmacy Association
	Independent Cancer Patients Voice	NHS Confederation
•	Macmillan Cancer Support	Scottish Medicines Consortium
•	Maggie's Centres	Welsh Government
•	Marie Curie	Welsh Health Specialised Services
•	South Asian Health Foundation	Committee
•	Specialised Healthcare Alliance	
•	Tenovus Cancer Care	Possible comparator companies
		 Advanz Pharma (methotrexate)
<u>He</u>	althcare professional groups	Amgen (filgrastim, pegfilgrastim)
•	Association of Cancer Physicians	Baxter (doxorubicin)
•	British Association of Urological	Chugai Pharma (lenograstim)
	Nurses	Cipla (methotrexate)
•	British Association of Urological	Hospira UK (carboplatin, cisplatin, geneitable, methors at viablestine)
	Surgeons British Corietries Society	gemcitabine, methotrexate, vinblastine)Medac GmbH (doxorubicin,
	British Geriatrics Society British Gynaecological Cancer Society	methotrexate)
	British Institute of Radiology	 Morningside Healthcare (methotrexate)
	British Oncology Pharmacy	 Napp Pharmaceuticals (pegfilgrastim)
	Association	Pfizer (methotrexate, doxorubicin,
•	British Psychosocial Oncology Society	filgrastim)

Provisional stakeholder list for the evaluation of Pembrolizumab with enfortumab vedotin for untreated locally advanced or metastatic urothelial cancer ID6332 Issue date: January 2024



Consultees	Commentators (no right to submit or appeal)
 British Society of Urogenital Radiology British Society of Urogynaecology British Uro-Oncology Group Cancer Research UK Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Urology Foundation Others Department of Health and Social Care NHS England 	 Roche (atezolizumab) Rosemont Pharmaceuticals (methotrexate) Sandoz (cisplatin, pegfilgrastim, filgrastim) Seacross Pharmaceuticals (doxorubicin) Sun Pharmaceutical (gemcitabine) Synchrony Pharma (gemcitabine) Therakind (methotrexate) Teva Pharma (lipegfilgrastim) Relevant research groups Cochrane UK Cochrane Urology Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research
	Associated Public Health groupsPublic Health WalesUK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of Pembrolizumab with enfortumab vedotin for untreated locally advanced or metastatic urothelial cancer ID6332 Issue date: January 2024



All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts, and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.